clinical trial · NCT07263919
Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
Akeso·phase2·recruiting·n = 90
Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaCadonilimab (AK104)CisplatinPaclitaxel
brief summary
This is a randomized, controlled, multi-center phase II/III study. All patients are resectable locally advanced thoracic esophageal squamous cell carcinoma (ESCC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of perioperative Cadonilimab combined with neoadjuvant chemotherapy versus neoadjuvant chemotherapy in patients with resectable ESCC.
started
Dec 19, 2025
primary completion
Mar 1, 2030
completion
Dec 1, 2031
last updated
Dec 31, 2025
official title
A Randomized, Controlled, Multi-center Phase II/III Clinical Trial of Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma (ESCC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol